Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Rhea-AI Summary

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and pherine-based intranasal treatments, has scheduled its fiscal year 2025 third quarter financial results conference call and webcast for February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The company will present results for the quarter ended December 31, 2024, along with a corporate update.

The event will be accessible via webcast through the company's website under the 'Events' section of the Investors area. Participants can register online to receive dial-in information and a unique PIN for the live call, with recommended joining 15 minutes before the start time. A replay will be available on Vistagen's website within 24 hours and remain accessible for at least 90 days.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, February 13, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 third quarter ended December 31, 2024, and provide a corporate update.

The conference call is being webcast live and a link can be found under “Events” in the Investors section of the Company's website.

Participants may register for the live call link HERE to receive the dial-in numbers and unique PIN to access the call. It is recommended that you join 15 minutes prior to the start of the event.

A webcast replay of the call will be available on Vistagen’s website within 24 hours after the end of the live conference call and will be accessible for at least 90 days.

About Vistagen

Headquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of clinical-stage product candidates from a new class of intranasal therapies called pherines. Pherines specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons, which activate olfactory bulb-to-brain neurocircuits without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits and differentiated safety. Vistagen’s neuroscience pipeline also includes an oral prodrug with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at www.Vistagen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250206443001/en/

Investors Inquiries:

Mark A. McPartland

markmcp@vistagen.com

Media Inquiries:

Michelle Wellington

mwellington@vistagen.com

Source: Vistagen

FAQ

When will Vistagen (VTGN) report its Q3 FY2025 earnings?

Vistagen will report its fiscal year 2025 third quarter results on February 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

How can investors access Vistagen's (VTGN) Q3 FY2025 earnings call?

Investors can access the call through a webcast link in the 'Events' section of Vistagen's website or by registering online to receive dial-in numbers and a unique PIN.

What period does Vistagen's (VTGN) Q3 FY2025 earnings report cover?

The earnings report covers Vistagen's fiscal quarter ended December 31, 2024.

How long will the replay of Vistagen's (VTGN) Q3 FY2025 earnings call be available?

A webcast replay will be available on Vistagen's website within 24 hours after the live call and will remain accessible for at least 90 days.